EPISODE · Feb 25, 2026 · 47 MIN
Biophytis｜當全世界長輩的肌肉都在悄悄流失，誰能成為暫緩肌少症無藥可醫的救世主？
from MDBros｜Paradigm Shifts in Healthcare · host MDBros
Biophytis 是家法國生技公司，核心產品 BIO101 為全球唯一進入第三期臨床試驗授權階段的肌少症候選藥物，透過活化 MAS 受體保護肌肉，Phase 2b 試驗顯示正向趨勢但主要終點未達統計顯著性，Phase 3（SARA-31）計畫收案 942 人；同步佈局 GLP-1 併用肌肉保護的 OBA 計畫，切入減重藥物導致肌肉流失的龐大市場。然而，截至 2025 年中現金僅 120 萬歐元、市值約 270 萬歐元，存亡繫於亞洲合資企業資金到位與否。 -- Hosting provided by SoundOn
Embed this episode
Ready to play
Biophytis｜當全世界長輩的肌肉都在悄悄流失，誰能成為暫緩肌少症無藥可醫的救世主？
0:00
47:21
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of MDBros｜Paradigm Shifts in Healthcare?
This episode is 47 minutes long.
When was this MDBros｜Paradigm Shifts in Healthcare episode published?
This episode was published on February 25, 2026.
Can I download this MDBros｜Paradigm Shifts in Healthcare episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!